An interventional study of Vit B12 and Vit B12 in Vitamin B 12 Deficiency, sponsored by Liaquat University of Medical & Health Sciences. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-18.
Sponsored by Liaquat University of Medical & Health Sciences · Not applicable, Interventional, and Prevention
Vitamin B12, a vital nutrient, plays a crucial role in red blood cell formation, neurological function, and DNA synthesis. Deficiency in B12 can lead to anemia, neurological symptoms such as tingling or numbness, and cognitive impairment. Oral B12 supplementation serves as an effective strategy to address B12 deficiency, especially for individuals with limited dietary intake or absorption issues. Regular B12 supplementation can help restore body B12 levels, alleviate deficiency-related symptoms, and support overall health and well-being.
The carrier system in oral vitamin B12 supplements plays a pivotal role in ensuring the stability and efficacy of the supplement. It helps protect the vitamin from degradation in the acidic environment of the stomach, enhancing its bioavailability. Additionally, the carrier system facilitates the transport of vitamin B12 across the gastrointestinal tract, promoting optimal absorption. By optimizing the delivery of B12 to the small intestine, the carrier system maximizes its potential for absorption into the bloodstream. Overall, the choice of carrier system significantly impacts the effectiveness of oral B12 supplementation in addressing deficiency and improving health outcomes.
Limited research exists regarding the exploration of various carrier systems used in oral B12 supplementation. This gap hinders a comprehensive understanding of how different carriers affect B12 absorption and efficacy. Further studies are needed to elucidate the optimal carrier system for maximizing B12 bioavailability and improving clinical outcomes. Expanding research in this area can enhance our knowledge and guide the development of more effective oral B12 supplements.
This study aims to compare the efficacy of sucrosomial and non-sucrosomial carrier systems in delivering vitamin B12 orally. By assessing absorption kinetics and clinical outcomes, we seek to determine the superiority of the sucrosomial carrier system in enhancing B12 bioavailability. Insights from this research could help in the development of more effective oral B12 supplements.
72 studies on the registry are indexed under Vitamin B 12 Deficiency; 10 are open to participants now.
This study's enrollment of 70 is close to the median of 65 across 44 interventional studies indexed under Vitamin B 12 Deficiency.
Browse Vitamin B 12 Deficiency studies →Liaquat University of Medical & Health Sciences is the lead sponsor of 55 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive oral single dose of 1000 mcg B-SUB® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive an oral single dose of 1000 mcg Mecogen SL® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive an oral single dose of 1000 mcg Sucrosomial® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive an oral single dose of 1000 mcg Evermin® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Participants will receive an oral single dose of 1000 mcg Neuromax® B12 supplement for 7 days.
Dietary Supplement: Vit B12
Sucrosomial® B12
B-SUB® B12
Mecogen SL® B12
Evermin® B12
Neuromax® B12
Supplementation effect on circulatory vitamin B12 levels
Changes in serum vitamin B12 levels
Time frame: Day 1, Day 3, Day 5, Day 7
Incidence of Treatment-Emergent Adverse Effects
Number of participants report treatment-emergent adverse effects
Time frame: one-week
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liaquat University of Medical & Health Sciences